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Abstract
Background: Malaria caused by Plasmodium falciparum can result in several different syndromes with severe
clinical consequences for the about 200 million individuals infected each year. During pregnancy, women living in
endemic areas become susceptible to malaria due to lack of antibodies against a unique P. falciparum membrane
protein, named VAR2CSA. This antigen is not expressed in childhood infections, since it binds chondroitin sulphate
A (CSA) expressed on the intervillous space in the placenta. A vaccine appears possible because women acquire
protective antibodies hindering sequestration in the placenta as a function of parity. A challenge for vaccine
development is to design small constructs of this large antigen, which can induce broadly protective antibodies. It
has previously been shown that one domain of VAR2CSA, DBL4-FCR3, induces parasite adhesion-blocking
antibodies. In this study, it is demonstrated that other domains of VAR2CSA also can induce antibodies with
inhibitory activity.
Methods: All VAR2CSA domains from the 3D7 and HB3 parasites were produced in Baculovirus-transfected insect
cells. Groups of three rats per protein were immunized and anti-sera were tested for surface reactivity against
infected erythrocytes expressing FCR3 VAR2CSA and for the ability to inhibit FCR3CSA parasite adhesion to CSA.
The fine specificity of the immune sera was analysed by VAR2CSA peptide arrays.
Results: Inhibitory antibodies were induced by immunization with DBL3-HB3 T1 and DBL1-3D7. However, unlike
the previously characterised DBL4-FCR3 response the inhibitory response against DBL1-3D7 and DBL3-HB3 T1 was
poorly reproduced in the second rounds of immunizations.
Conclusion: It is possible to induce parasite adhesion-blocking antibodies when immunizing with a number of
different VAR2CSA domains. This indicates that the CSA binding site in VAR2CSA is comprised of epitopes from
different domains.
Background
Pregnancy associated malaria (PAM) causing maternal
anaemia, low birth weight and stillbirth, is a severe man-
ifestation of Plasmodium falciparum infection [1]. PAM
is caused by infected erythrocytes (IE) that sequester in
the intervillous space of the placenta [2]. The ability to
sequester in the vascular bed whereby the parasite
avoids immune mechanisms in the spleen is a hallmark
of the particular virulence of P. falciparum. The IE bind
host receptors on various endothelia through antigens
called P. falciparum erythrocyte membrane protein 1
(PfEMP1). The PfEMP1 protein family, encoded by the
var genes, is constituted of large proteins of 150-350
kDa with several Duffy-binding-like (DBL) domains. Dif-
ferent PfEMP1 molecules have different receptor specifi-
cities, and clonal switching between expression of the
various var gene products, in a mutually exclusive man-
ner, allows the parasite to modify its adhesion properties
accordingly (reviewed in [3]). There are about 60 copies
of highly different var genes in each parasite genome
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and a high sequence variation among genomes [4-6].
Expression of different PfEMP1 variants allow the para-
sites to escape previously acquired antibody responses,
and clinical protection occurs when a large repertoire of
variant specific antibodies allows the host to control the
infection [7]. After repeated infections during childhood
in endemic areas the acquired repertoire of antibodies
against the variant surface antigens will progressively
protect against variants expressed during severe, mild
and asymptomatic infections [8,9]. During pregnancy
the parasite again escapes acquired immunity by expres-
sing variants not encountered during childhood disease.
This is mediated by parasites occupying a new niche,
the developing placenta. The interaction between para-
site antigens on the surface of the IE and chondroitin
sulphate A (CSA) in the placenta is one of the most
direct associations between binding phenotype and dis-
ease outcome in falciparum malaria. Placental parasites
and parasite lines selected for CSA binding in vitro
express a unique var gene named var2csa [10,11].
VAR2CSA is expressed on the surface of IE panned on
CSA and on IE isolated from infected placentas [12,13]
and parasite clones where the var2csa gene is disrupted
lose the ability to bind CSA [14]. Several domains and
regions of VAR2CSA have been shown to bind CSA in
vitro, however, the specificity of single VAR2CSA
domain binding to CSA does not seem to be exclusive
for CSA type glycans [15-18].
Women in malaria endemic areas acquire antibodies
that protect against PAM as a function of parity [1].
The mechanism of protection is suggested to be based
on antibodies that block binding of IE to CSA [19].
Likewise, high anti-VAR2CSA IgG levels are correlated
with protection against the clinical consequences of
PAM [13]. These findings suggest that it is feasible to
develop a VAR2CSA-based vaccine to protect women in
malaria endemic areas against PAM. A challenge for
vaccine development is to define VAR2CSA constructs
of a size compatible with protein-vaccine production,
which elicit pan-reactive antibodies that abrogate bind-
ing of parasites in the placenta. It has previously been
shown that antibodies induced against DBL6-FCR3 par-
tially inhibited parasite binding and that this inhibitory
activity was only present in serum collected during the
immunization but absent in the final bleed [20].
Recently, it was shown that DBL4-FCR3 induced a
broadly IgG based parasite adhesion-blocking response,
which increased during the immunizations and was
highly reproducible in subsequent immunizations with
the same antigen [21]. These DBL4 antibodies are cur-
rently being tested for the capacity to inhibit binding to
CSA in a large panel of placental parasites. It is possible
that the DBL4-FCR3 antibodies do not inhibit all iso-
lates due to sequence variation within VAR2CSA. In
that case an effective PAM vaccine would need to be
based on multiple VAR2CSA serotypes. The aim of this
study was to define additional DBL domain, which can
induce parasite adhesion-blocking antibodies in order to
make a multidomain vaccine, which presumable could
protect women against multiple P. falciparum genotypes.
Two domains, DBL1-3D7 and DBL3-HB3 T1 were
shown to induce a cross-reactive inhibitory response,
however, in line with the published data on DBL6-FCR3
the inhibitory response was either not sustained during




Parasite culture was grown as previously described [22].
In brief, parasites were maintained in culture using 5%
haematocrit of human blood group 0+ blood in parasite
medium consisting of RPMI-1640 supplemented with 25
mmol/l sodium bicarbonate (Sigma-Aldrich), 0.125 μg/
ml gentamycin, 0.125 μg/ml Albumax II (Invitrogen)
and 2% normal human serum. To select for VAR2CSA
expression, IE were repeatedly panned on BeWo-cells.
All isolates were mycoplasma negative and were regu-
larly genotyped using nested GLURP and MSP-2 pri-
mers in a single PCR step.
Protein production
All VAR2CSA constructs were based on native var2csa
and cloned from genomic parasite DNA. Control con-
structs were cloned from DNA from either FCR3 var1-
DBL3g or 3D7 PF08_0141-DBL2b. Gene fragments were
cloned into the Baculovirus vector, pAcGP67-A (BD
Biosciences) modified to contain the V5 epitope
upstream of a histidine tag in the C-terminal end of the
constructs. Linearized Bakpak6 Baculovirus DNA (BD
Biosciences) was co-transfected with pAcGP67-A into
Sf9 insect cells for generation of recombinant virus par-
ticles. Histidine-tagged recombinant protein was purified
on Ni2+ sepharose columns from the supernatant of
Baculovirus infected High-Five insect cells using an
ΔKTAxpress purification system (GE-Healthcare).
Rat immunizations
Wistar rat anti-sera raised against the VAR2CSA
domains from HB3 and 3D7 were produced by injection
of 40 μg of recombinant protein in Freund’s complete
adjuvant, followed by two booster injections of 40 μg of
protein in Freund’s incomplete adjuvant at 2 1/2-week
intervals. Anti-sera were collected eight days after the
final boosting injection. All immunizations induced anti-
bodies against the recombinant proteins as measured by
Enzyme-Linked Immunosorbent Assay (ELISA) of the
final bleed. Immunizations with the DBL3-HB3 T1 pro-
tein were done five times and six bleeds were collected.
The endpoint titer of selected serum samples and IgG
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were determined by ELISA. All procedures regarding
animal immunizations complied with European and
national regulations.
Flow cytometry and binding inhibition assay
Flow-cytometry was used to test the reactivity of rat
serum to VAR2CSA on the surface of the IE. In brief,
parasite cultures were enriched to contain late tropho-
zoite and schizont stage parasites by exposure to a
strong magnetic field. Aliquots (2 × 105 IE) were
labelled by ethidium bromide and sequentially exposed
to 10 μl rat serum and 1 μl anti-rat IgG-FITC (Zymax,
Invitrogen). Data was acquired using a FC500 flow-cyt-
ometer (Beckman Coulter). All samples relating to a
particular parasite isolate were processed and analysed
in a single assay. Parasite binding assays were done as
described in [21]. Briefly, 2 × 105 tritium labelled late-
stage IE and 15 μl rat serum or IgG in a total volume of
100 μl were added in quadruplicates to wells coated
with 2 μg/ml of the commercially available chondroitin
sulphate proteoglycan (CSPG) decorin (D8428, Sigma-
Aldrich). The binding to decorin was abrogated by solu-
ble CSA (C9819, Sigma-Aldrich) and chondroitinase
treatment. After incubation for 30 min at 37°C unbound
IE were washed away by resuspension performed by a
pipetting robot (Beckman Coulter). The proportion of
adhering IE was determined by liquid scintillation
counting on a Topcount NXT (Perkin-Elmer).
Pepscan analysis
A peptide array containing 442 31mer peptides corre-
sponding to the extracellular part of 3D7 VAR2CSA was
used for antibody binding studies [23]. The sequences of
the peptides had an overlap of six residues and the pur-
ity of the peptides was expected to be 70% or higher.
The peptides were synthesized with a cysteine at amino
acid position 15 allowing some secondary structure.
Structural modelling and mapping of residues was done
as described [23].
Results
Cloning and expression of VAR2CSA DBL proteins
To identify other domains than the published DBL4-
FCR3 [21], which could induce inhibitory antibodies, all
single domains from 3D7 VAR2CSA and HB3
VAR2CSA were cloned (Table 1). Published data on
rabbit antibodies induced against all 3D7 VAR2CSA
DBL domains showed that these antibodies reacted with
IE [24] but failed to inhibit parasite binding (data not
shown). The 3D7 VAR2CSA DBL domains were this
time cloned and expressed with the same border defini-
tions as recently presented for the FCR3 domains [21].
The HB3 parasite genome harbours two different
var2csa genes (T1 and T2) and both variants were
cloned and expressed. However, the DBL2 T2 and the
DBL6 T2 did not express in sufficient amounts for
immunizations and thus these two domains were not
included in the analysis (Table 1).
Reactivity of rat IgG against native VAR2CSA and
capability to block parasite adhesion to CSA
The VAR2CSA proteins were used to immunize groups
of three rats. It was not possible to test inhibition of
3D7 binding, since this parasite binds poorly to CSA.
With regard to the HB3 parasite, this strain harbours
two variants of var2csa in the genome and panning on
CSA results in expression of both var2csa variants.
Therefore, all sera were evaluated on the heterologous
and strongly CSA adhering parasite strain, FCR3CSA.
Accordingly only cross-reactive antibodies are measured,
which, in essence correspond to the response one would
want from a given vaccine. All 3D7 proteins except
DBL6 induced cross-reactive IgG reacting with native
VAR2CSA on the surface of IE. DBL1 and DBL2
induced the highest reacting IgG (Figure 1A). The HB3
proteins induced generally poorly cross-reactive antibo-
dies with the exception of DBL3 T1 with a MFI value of
15 (Figure 1B). The DBL5 domain has in several publi-
cations been shown to induce strong and cross-reactive
IgG, however, the three different DBL5 domains pro-
duced here induced IgG, which reacted poorly with
FCR3CSA (Figure 1A and 1B). The sera were tested for
the ability to inhibit FCR3CSA binding to CSA. Interest-
ingly, the DBL1-3D7 and DBL3-HB3 T1 sera had inhibi-
tory activity and almost completely blocked the parasite
adhesion to CSA (Figure 1C and 1D, respectively). None
Table 1 List of immunogens. 3D7 and HB3 VAR2CSA
constructs.




















DBL6 T1 Not Expressed
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of the other HB3 proteins elicited inhibitory antibodies
when comparing to the negative control sera, whereas
all the other 3D7 DBL domain sera appeared to have a
weak adhesion-interfering effect.
Reproducibility of the inhibitory response
To further analyse the inhibitory response induced by
DBL3-HB3 T1 and DBL1-3D7 two groups of rats were
immunized and the different bleeds during the immuni-
zation procedure were analysed. The rats were
immunized twice before the first bleed was collected at
day 21. The sera were tested in two different assays
measuring the capacity to react with native VAR2CSA
on IE and for the capacity to inhibit parasite binding to
CSA in vitro. The first bleed from the DBL3-HB3 T1
immunizations blocked parasite adhesion to CSA but
did not stain the surface of the parasites (Figure 2A).
The inhibition remained at the same level for the subse-
quent four bleeds, whereas the surface reactivity
Figure 1 Surface reactivity and inhibitory capacity of serum specific for DBL domains of VAR2CSA from 3D7 and HB3. A and B: Sera
from three rats immunized with the same recombinant protein were pooled and tested in FACS. The surface reactivity was measured using 10
μl serum in a total volume of 100 μl against 2 × 105 late trophozoite and schizont-infected erythrocytes (IE). To measure the level of rat IgG
bound to the surface of the IE 1 μl rabbit anti-rat IgG-FITC was used in a total volume of 100 μl and the mean fluorescence intensity of 5000
cells was analysed and shown in white bars. The assays were performed twice with similar results. C & D: For inhibition of IE binding to CSPG,
15 μl of rat serum in a total volume of 120 μl were tested in triplicate wells of 96 well Falcon plates coated with 2 μg/ml CSPG. Serum pools
and tritium labelled parasites (2 × 105) were added simultaneously to the wells and incubated for 2 hours. Hereafter the plate was washed using
a pipetting robot and the remaining cells were harvested on a filter plate and counted using scintillation. The mean percentage of binding is
shown relative to binding in wells without inhibitor. Error bars are standard deviations of triplicate measurements. The assays were performed
twice with similar results. In both types of assays serum from rats immunized with FCR3 var1-DBL3g and 3D7 PF08_0141-DBL2 b were used as
negative controls.
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increased. However, at the final bleed, taken 40 days
after the last immunization, the IgG remained immuno
fluorescence assay (IFA) positive, but no inhibitory effect
was detected. In a repeated immunization experiment
three new rats were immunized with DBL3-HB3 T1.
This time, adhesion-blocking antibodies were not
detected in any of the bleeds, whereas the IgG reactivity
against FCR3CSA increased during the immunizations
(Figure 2B). When repeating the DBL1-3D7 immuniza-
tions, there was no appreciable anti-adhesive effect of
the serum in any of the bleeds. Only the third bleed
appeared to react with the surface of FCR3CSA,
although this reactivity was not present in the final
bleed (Figure 2C).
Epitope mapping of induced anti-VAR2CSA IgG
The fine specificity of the antibody response in inhibi-
tory and non-inhibitory sera was analysed using a pep-
tide array covering the extracellular part of 3D7
VAR2CSA consisting of 442 peptides of 31mer each
with an overlap of six residues. The peptides were
Figure 2 Surface reactivity and inhibitory capacity of serum from rats immunized again with DBL3-HB3 T1 and DBL1-3D7. Surface
reactivity (white bars) and inhibition of binding (black bars) assays were performed as described in Figure 1. White bars represent the ratio
between the MFI of a given sample divided by MFI of the negative control. Black bars represent the ratio between the counts per minute (CPM)
in a given sample divided by the CPM of the positive control. Error bars indicate standard deviations. A and B: Pools of sera from consecutive
blood sampling from rats immunized with DBL3-HB3 T1. C Pools of sera from consecutive blood sampling from rats immunized with DBL1-3D7.
The assays were performed twice with similar results.
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bound to the chip using a cysteine at position 15. From
the DBL1-3D7 immunizations, the original inhibitory
serum sample was analysed on the chip. In addition sera
from two rats from the subsequent immunizations,
which did not induce inhibitory antibodies (Figure 3A),
were analysed. In all the sera, there was a high reactivity
against eight to 17 peptides of the total 63 peptides cov-
ering the DBL1 domain and three major B-cell epitopes
were detected. Two of these epitopes reacted with IgG
from all three sera, of which one was located between
subdomain S1 and S2 (marked with a blue horizontal
bar in figure 3A) and the other one at the beginning of
subdomain S2 (orange in figure 3A), whereas the third
epitope was predominantly recognized by the inhibitory
serum and located in subdomain S3 (red horizontal bar,
figure 3A). For DBL3-HB3 T1 the IgG reactivity from
two rat sera were analysed, which inhibited parasite
binding, and one rat serum that did not inhibit binding
(Figure 3B). Two regions at the beginning of the S2 and
S3 subdomain, respectively, were targeted by IgG from
all three sera. However, only one peptide within each
region was recognized by the non-inhibitory serum. The
inhibitory DBL4-FCR3 antibodies published recently
[21] were also mapped for epitopes using the same pep-
tide array. It was difficult to identify a DBL4-FCR3
serum sample which did not induce inhibitory antibo-
dies, therefore, a non-inhibitory DBL4-3D7 serum sam-
ple was chosen for comparison in the pepscan analysis
(Figure 3C). Similar to the antibody reactivity induced
against DBL1 and DBL3, a B-cell epitope was identified
in the N-terminal part of the domain spanning the S1
and S2 subdomain border (orange horizontal bar in fig-
ure 3C) as well as a B-cell epitope in S3 (blue horizontal
bar in figure 3C). All identified B-cell epitope regions
were mapped on a model of the corresponding domain
(Figure 3A-C).
Discussion
Identification of the var2csa gene is one of the major
recent advances in the search for a vaccine against
PAM. The low level of polymorphism in VAR2CSA,
relative to other PfEMP1 molecules [25], and the rapid
acquisition of VAR2CSA-specific IgG as a function of
parity after natural infections [13], support the potential
of developing parts of this antigen into a vaccine. PAM
pathogenesis is partly due to host immune responses in
the placenta [26], and it may not be optimal to induce
IgG that are not adhesion-inhibitory, since this may
enhance unwanted inflammatory immune responses in
the placental tissue. IgG that hinder parasite binding
would reduce the harmful inflammatory response in the
placenta and depending on the IgG isotype, these anti-
bodies could also be efficiently opsonising. The strategy
for vaccine development is therefore to induce anti-
adhesive antibodies [27]. It has previously been shown
that the DBL4 domain from FCR3 elicits a strong inhibi-
tory IgG response, which was highly reproducible in
subsequent immunizations [21]. This has raised the
question whether DBL4 is the only part of VAR2CSA
involved in CSA adhesion, and if other domains are
indeed involved in the adhesion process, and accordingly
it would be of interest to define these to make a multi-
domain vaccine. Interestingly, in this study it is shown
that two domains different from DBL4 can also elicit
inhibitory antibodies. This indicates that the CSA bind-
ing region of VAR2CSA is comprised of epitopes from
multiple domains, which is in line with published data
showing that single recombinant domains from
VAR2CSA do not bind specifically to CSA [15,17].
DBL4 is the most conserved VAR2CSA domain; how-
ever this domain does contain some variable regions,
primarily located in the flexible loops [28]. At present, it
is not known whether the anti-DBL4 IgG can inhibit
parasite adhesion of all VAR2CSA expressing isolates.
Therefore, a VAR2CSA vaccine may be comprised of
DBL4 from different var2csa genes or FCR3 DBL4 and
another DBL domain. From a vaccine development
point of view, it is thus promising that it is possible to
induce highly inhibitory antibodies with other domains
than DBL4-FCR3. It is surprising though that a strong
inhibitory antibody response could not be induced with
the DBL4 domains from 3D7 and the two variants of
HB3. In addition, the induced inhibitory response
towards DBL3-HB3 T1 and DBL1-3D7 appeared to be
difficult to reproduce in subsequent immunizations.
Based on the above findings, it is suggested that anti-
bodies can block a single unique CSA binding-site pre-
sent in the quaternary structure of VAR2CSA, or block
the assembly of such quaternary structure to interfere
with binding, and that these antibodies can be induced
by a number of different VAR2CSA domains. This
hypothesis is in line with previously published data sug-
gesting that VAR2CSA is presented as a globular protein
on the surface of IE [23]. However, it seems difficult to
focus the immune response in the animals towards the
correct epitopes, which is substantiated by the fact that
the inhibitory response is either lost during the immuni-
zation schedule, or not induced at all despite the pre-
sence of high reactivity in ELISA.
The binding inhibitory activity was not induced in all
immunizations; despite the presence of a specific and
high titered immune response. This could be due to an
erratic animal response to the immunogen caused by an
unstable tertiary structure of the antigens used for
immunizations. Another explanation could be differ-
ences in the fine specificity of the sera affecting the
functionality of the induced IgG response, due to selec-
tion for reactivity against loop regions with high
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Figure 3 Fine epitope mapping of anti-VAR2CSA IgG. The fine specificity of the antibody response in inhibitory and non-inhibitory sera was
analysed using a peptide array covering the extracellular part of 3D7 VAR2CSA. Inhibitory rat sera are shown with red vertical bars and non-
inhibitory sera with black or blue vertical bars. IgG from three individual rats immunized with DBL1-3D7 (A) and DBL3-HB3 T1 (B) were analysed
and IgG from two individual rats immunized with DBL4-FCR3 (red bars) and DBL4-3D7 (black bars) (C). B-cell epitopes are marked on the graph
with horizontal bars in blue, red or orange and were mapped on a structural model of the corresponding domain based on the 3D7 sequence.
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sequence variation, which this study would be sensitive
to, since heterologous responses are measured. To study
the fine specificity of the different sera, the IgG reactiv-
ity against VAR2CSA peptides was measured. In general,
it was noted that the measured antibody reactivity
against the different domains located to the same
regions, and that a large central region of the domain
did not contain any continuous epitopes. Interestingly,
the large epitope in DBL3 located in a flexible loop is
identical to the loop region shown to become structured
upon CSA interaction [29]. DBL domains are compact
and highly structured proteins and it is likely that many
antibodies will be targeting discontinuous epitopes and
thus would not be detected in the peptide array. How-
ever, it is clear from the data that different immuniza-
tions with the same antigen do not give the same fine
specificity each time, which likely reflects the variation
in the inhibitory activity of the induced antibodies.
Conclusions
VAR2CSA consists of six DBL domains. The data pre-
sented here show that it is possible to induce parasite
adhesion-blocking antibodies when immunizing animals
with the domains DBL1 and DBL3, which indicates that
the CSA binding site in VAR2CSA is comprised of
regions from different domains. However, a robust and
reproducible response with these proteins was not indu-
cible. Epitope mapping shows differences in the fine
specificity of the inhibitory and non-inhibitory sera.
Accordingly if the Baculovirus produced DBL1-3D7 and
DBL3-HB3 T1 antigens are to be used in a vaccine,
further research is needed to define and focus the
immune response towards the relevant epitopes.
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